Reports show that global manufacturers of medicines have been prepared to cut drugs prices by 61%, on average, in order to achieve reimbursement in China.
Reuters reported that the National Healthcare Security Administration (NHSA) was able to announce the additional of several high-profile medicines to the list, including Pertuzumab (Roche) and Omalizumab (Novartis) thanks to the reductions, giving China the “lowest prices globally” for the additions.
“Tumor and diabetes medicines saw an average price cut of about 65%, according to the NHSA.
“Other drugs added included Adalimumab, an arthritis treatment which AbbVie (ABBV.N) sells as Humira, one of the top-selling drugs in the world.”
Find out more here.